ProNova Solutions and alphaXRT sign exclusive agreement

ProNova Solutions, a leading manufacturer of next generation proton therapy equipment, has signed an exclusive agreement with AlphaXRT to represent ProNova’s innovative treatment solution throughout Australia and New Zealand.

“We are excited to partner with one of the leading distributors in the region to assist ProNova with delivering state-of-the-art proton therapy solutions to this key part of the world,” said Tom Welch, President of ProNova Proton Centers.  “We have had a long and trusted relationship with AlphaXRT that goes back to our days with CTI.”

“ProNova’s complete solution is ideal for Australasia. They offer the latest technology available in proton therapy with a smaller footprint and cost-effective operation, and also bring true clinical and commercial expertise through their own treatment centre, ProVision in Tennessee. We are delighted to be chosen to represent ProNova.” says Richard Neale, Managing Director of AlphaXRT.

Proton therapy is a superior form of external beam therapy using proton particle properties to accurately deliver all radiation inside cancer tumours while sparing healthy tissue. Proton therapy is becoming the treatment of choice for head and neck, brain, spine, prostate and others, especially in paediatric cases due to reduced side effects compared to alternative treatments.

The agreement between ProNova and AlphaXRT opens the possibility for Australian cancer treatment centres to access one of the most advanced cancer treatment techniques in the world and allow cutting edge treatments to be available to patients in Australia and New Zealand.

AlphaXRT is the leading distributor of software and equipment used in the treatment of cancer in Australia and represents a wide range of respected international suppliers. The dedicated sales and support team at AlphaXRT are highly experienced in the field of radiation therapy and serve all radiation therapy centres in Australia and New Zealand.

ProNova is committed to making proton therapy accessible to a greater number of patients and physicians worldwide. Founded by the leaders of CTI Molecular Imaging, ProNova’s team brought positron emission tomography (PET) technology out of the laboratory and made it a clinical reality for millions of cancer patients.

For more information: and

Disclaimer: the ProNova SC360 has not been cleared by the U.S Food and Drug Administration [FDA] for commercial distribution in the US and is not available for commercial distribution at this time.